Volume 1 (2013): Issue 2

IM botulinum toxin-A improves ambulation in severe haemophilia and cerebral palsy

Open Access | | Creative Commons Attribution NonCommercial NoDerivatives
Melanie Bladen
Karen Edwards
Kate Khair
Eleanor Main

Abstract

Abstract Introduction

The use of BtA in spasticity management is well documented in the literature for the management of hypertonicity in children with cerebral palsy.

Methods

We report a case of a 2-year-old boy with severe haemophilia and cerebral palsy who received intramuscular injections of botulinum toxin-A (BtA) to reduce his spastic diplegia lower limb hypertonicity.

Results

Following treatment, clinical and formal assessments demonstrated positive changes in ambulation, tolerance of orthotics, functional abilities and musculoskeletal range of movement and no adverse bleeding side effects.

Conclusion

The use of BtA should be considered for the management of hypertonicity in children with haemophilia and cerebral palsy.

Article

View Full Article

References

  • 1. Carr LJ, Cosgrove AP, Gringas P, Neville BGR, on behalf of the UK Botulinum Toxin and cerebral palsy working party. Position paper on the use of botulinum toxin in cerebral palsy. Arch Dis Child 1998; 79: 271-273
  • 2. Delgado MR, Hirtz D, Aisen M, et al. Practice Parameter: Pharmocologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review) Report of the quality standards subcommittee of the child neurology society. Neurology 2010; 74: 336-343.
  • 3. Love SC, Novak I, Kentish M, et al. Botulinum toxin assessment, intervention and after care for lower limb spasticity in children with cerebral palsy:international consensus statement. European J Neurol 2010, 17 (Suppl) 9-37.
  • 4. Corry IS, Cosgrove AP, Duffy CM, et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equines: a randomized prospective trial. J Ped Orthopaedics 1998, 18, 304-311.
  • 5. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36: 386-396.
  • 6. Graham HK, Aokia KR, Autti-Ramob, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000; 11: 67-79.
  • 7. Ward A. Long-term modifications of spasticity. J Rehabil Med 2003; 35: 60-65.
  • 8. de Paiva A, Muenier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotixin type A poisoning:biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96: 3220-5.
  • 9. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. European J Neurol 1999; 6 (Suppl): 23-35.
  • 10. Ashworth B. Preliminary trial of carisoprodal in multiple sclerosis. Practitioner 1964; 192: 540-542.
  • 11. Palisanao R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997; 39: 214-233.

PDF Download

Download PDF

Open in full-page viewer

Authors

  • Melanie Bladen

    melanie.bladen@gosh.nhs.uk
    Haemophilia Centre Great Ormond St Hospital for Children NHS Trust, London, UK

  • Karen Edwards

    Movement Disorder Team, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street London WC1N 3JH, UK

  • Kate Khair

  • Eleanor Main

    Portex Department, 6th Floor, Cardiac Wing, Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK